151 – 160 of 368
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Kaveolerinvaginationer i cellmembranet med komplex funktion. Defekter i kaveolanlag kopplade till svåra medfödda sjukdomar.
(
- Contribution to journal › Scientific review
-
Mark
Human urinary bladder smooth muscle is dependent on membrane cholesterol for cholinergic activation.
(
- Contribution to journal › Article
-
Mark
Open partial nephrectomy for renal cell cancer in a medium patient volume centre: Is high quality possible?
(
- Contribution to journal › Article
-
Mark
Toll-Like Receptor 4 Promoter Polymorphisms: Common TLR4 Variants May Protect against Severe Urinary Tract Infection.
(
- Contribution to journal › Article
-
Mark
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
(
- Contribution to journal › Article
-
Mark
Re: Richard J. Sylvester, Willem Oosterlinck. An Immediate Instillation after Transurethral Resection of Bladder Tumor in Non-Muscle-Invasive Bladder Cancer: Has the Evidence Changed? Eur Urol 2009;56;43-5.
(
- Contribution to journal › Letter
- 2009
-
Mark
Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study
(
- Contribution to journal › Article
-
Mark
Characterizing Escherichia coli asymptomatic bacteriuria (ABU) - what drives their successful silent colonization?
2009) 61st Conference of the Deutschen-Gesellschaft-fur-Hygiene-und-Microbiologie In International Journal of Medical Microbiology 299. p.54-54(
- Contribution to journal › Published meeting abstract
-
Mark
Effects of repeated botulinum toxin a injection therapy in patients with sympthomatic neurogenic detrusor overactivity - a 3-year follow up
2009) 39th Annual Meeting of the International-Continence-Society In Neurourology and Urodynamics 28(7). p.35-35(
- Contribution to journal › Published meeting abstract
-
Mark
Desmopressin, as a "Designer-Drug," in the Treatment of Overactive Bladder Syndrome
(
- Contribution to journal › Article